Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Personalis stock
Learn how to easily invest in Personalis stock.
Personalis Inc is a diagnostics & research business based in the US. Personalis shares (PSNL) are listed on the NASDAQ and all prices are listed in US Dollars. Personalis employs 325 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Personalis
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – PSNL – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Personalis stock price (NASDAQ: PSNL)Use our graph to track the performance of PSNL stocks over time.
Personalis shares at a glance
|Latest market close||$3.73|
|52-week range||$3.13 - $25.20|
|50-day moving average||$4.41|
|200-day moving average||$11.25|
|Wall St. target price||$19.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-1.82|
Buy Personalis shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Personalis stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Personalis price performance over time
|1 week (2022-06-30)||8.12%|
|1 month (2022-06-07)||-2.86%|
|3 months (2022-04-05)||-55.11%|
|6 months (2022-01-07)||-71.13%|
|1 year (2021-07-07)||-84.16%|
|2 years (2020-07-07)||-73.81%|
|3 years (2019-07-05)||22.3|
|5 years (2017-07-03)||N/A|
|Revenue TTM||$79.8 million|
|Gross profit TTM||$31.7 million|
|Return on assets TTM||-13.07%|
|Return on equity TTM||-25.52%|
|Market capitalisation||$154.5 million|
TTM: trailing 12 months
Personalis share dividends
We're not expecting Personalis to pay a dividend over the next 12 months.
Personalis share price volatility
Over the last 12 months, Personalis's shares have ranged in value from as little as $3.13 up to $25.195. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Personalis's is 1.7391. This would suggest that Personalis's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.
Personalis in the news
Strong week for Personalis (NASDAQ:PSNL) shareholders doesn't alleviate pain of one-year loss
Frequently asked questionsWhat percentage of Personalis is owned by insiders or institutions?
Currently 1.583% of Personalis shares are held by insiders and 90.043% by institutions. How many people work for Personalis?
Latest data suggests 325 work at Personalis. When does the fiscal year end for Personalis?
Personalis's fiscal year ends in December. Where is Personalis based?
Personalis's address is: 1330 O?Brien Drive, Menlo Park, CA, United States, 94025 What is Personalis's ISIN number?
Personalis's international securities identification number is: US71535D1063 What is Personalis's CUSIP number?
Personalis's Committee on Uniform Securities Identification Procedures number is: 71535D106
More guides on Finder
How to buy Citrine Global (CTGL) stock when it goes public
Everything we know about the Citrine Global IPO, plus information on how to buy in.
How to buy Genelux Corporation (GNLX) stock when it goes public
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
How to buy Magic Empire Global (MEGL) stock when it goes public
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Ask an Expert